DK1425007T3 - Anvendelse af C2-substituerede indan-1-ol-systemer til fremstilling af medikamenter til profylaxe eller behandling af obesitas - Google Patents

Anvendelse af C2-substituerede indan-1-ol-systemer til fremstilling af medikamenter til profylaxe eller behandling af obesitas

Info

Publication number
DK1425007T3
DK1425007T3 DK02772165T DK02772165T DK1425007T3 DK 1425007 T3 DK1425007 T3 DK 1425007T3 DK 02772165 T DK02772165 T DK 02772165T DK 02772165 T DK02772165 T DK 02772165T DK 1425007 T3 DK1425007 T3 DK 1425007T3
Authority
DK
Denmark
Prior art keywords
prophylaxis
obesity
systems
treatment
drugs
Prior art date
Application number
DK02772165T
Other languages
English (en)
Inventor
Gerhard Jaehne
Volker Krone
Martin Bickel
Matthias Gossel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1425007T3 publication Critical patent/DK1425007T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02772165T 2001-08-31 2002-08-17 Anvendelse af C2-substituerede indan-1-ol-systemer til fremstilling af medikamenter til profylaxe eller behandling af obesitas DK1425007T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10142666A DE10142666A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas

Publications (1)

Publication Number Publication Date
DK1425007T3 true DK1425007T3 (da) 2006-03-13

Family

ID=7697236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02772165T DK1425007T3 (da) 2001-08-31 2002-08-17 Anvendelse af C2-substituerede indan-1-ol-systemer til fremstilling af medikamenter til profylaxe eller behandling af obesitas

Country Status (13)

Country Link
US (2) US20030134879A1 (da)
EP (1) EP1425007B1 (da)
JP (1) JP2005503397A (da)
AT (1) ATE308321T1 (da)
AU (1) AU2002336984B2 (da)
CA (1) CA2458526A1 (da)
DE (2) DE10142666A1 (da)
DK (1) DK1425007T3 (da)
ES (1) ES2250710T3 (da)
IL (2) IL160605A0 (da)
MX (1) MXPA04001852A (da)
PE (1) PE20030335A1 (da)
WO (1) WO2003020263A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
CN102333528B (zh) * 2009-01-26 2013-12-18 台北医学大学 蕨素化合物用于治疗糖尿病及肥胖之用途
TWI799691B (zh) * 2019-03-29 2023-04-21 景凱生物科技股份有限公司 具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2345146A1 (fr) * 1976-03-23 1977-10-21 Logeais Labor Jacques Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol
EP0009554B1 (de) * 1978-07-27 1983-04-27 Schering Aktiengesellschaft Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
JPH01503777A (ja) * 1985-10-04 1989-12-21 マツジヨ‐ニ‐ウインスロツプ・ソチエタ・ペル・アチオニ 縮合脂環式アミノアルコール類
MX13484A (es) 1987-10-19 1993-05-01 Pfizer Procedimiento para la obtencion de tetralinas, cromanos y compuestos relacionados, sustituidos
ATE246670T1 (de) * 1995-12-06 2003-08-15 Venantius Ltd Indandimerverbindungen mit relaxierender wirkung auf die glatten muskeln und/oder mit mastzellen stabilisiernder und/oder entzuendungshemmender wirkung
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
DE10142660A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142662B4 (de) * 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142667B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2458526A1 (en) 2003-03-13
PE20030335A1 (es) 2003-05-20
DE50204801D1 (de) 2005-12-08
US20050080057A1 (en) 2005-04-14
ATE308321T1 (de) 2005-11-15
MXPA04001852A (es) 2004-06-15
IL160605A0 (en) 2004-07-25
EP1425007A1 (de) 2004-06-09
AU2002336984B2 (en) 2006-10-26
IL160605A (en) 2010-12-30
DE10142666A1 (de) 2003-03-20
ES2250710T3 (es) 2006-04-16
WO2003020263A1 (de) 2003-03-13
EP1425007B1 (de) 2005-11-02
US7763662B2 (en) 2010-07-27
JP2005503397A (ja) 2005-02-03
US20030134879A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
NO20052739L (no) CCR5-antagonister som medikamenter
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
NO20081844L (no) Terapeutiske forbindelser
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20073765L (no) Forbindelser for behandling av flaviviridae
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
NO20060977L (no) Mitokinon-derivater anvendt som mitokondrielle malsokende antioksidanter
ATE410426T1 (de) Heterocyclische verbindungen alsccr5-antagonisten
DK1246808T3 (da) 1,2-diarylbenzimidazoler til behandling af sygdomme, som er associeret med en mikroglia-aktivering
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
DK1173176T3 (da) Anvendelse af polycycliske 2-aminothiazolsystemer til fremstilling af medikamenter til forebyggelse eller behandling af obesitas
BR0208038A (pt) Uso de um ou mais componentes saudáveis e método para a administração de um componente saudável.
MXPA04001847A (es) Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.
WO2004099165A3 (en) Heterocyclic compounds and hydro isomers thereof
DK1441723T3 (da) Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension
PE20030335A1 (es) Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
ATE385792T1 (de) Verwendung von derivaten von c2-substituierten indan-1-ol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas